AI-Mind partners present new findings at SEPNECA 2025
The AI-Mind consortium is proud to announce contributions to the XIV Congress of the Spanish Society of Psychophysiology and Cognitive and Affective Neuroscience (SEPNECA), which will take place on 10 October 2025. Researchers from the Complutense University of Madrid (UCM), will present their latest results as part of the symposium “Advances in the Early Detection of Cognitive Decline and Neurodegeneration.”
Advancing early detection of Alzheimer’s-type dementia
Adults diagnosed with Mild Cognitive Impairment (MCI) face an annual risk of 10–15% of progressing to Alzheimer’s-type dementia (AD). While some patients experience this conversion, others remain stable over time, highlighting the need to better understand and predict disease trajectories.
The AI-Mind project, which recruited 1,000 participants across four European countries, has followed participants with a comprehensive set of neuropsychological, neurophysiological and blood biomarker assessments over four visits across two years. The team from UCM analysed 20 MCI patients who converted to AD during follow-up (MCIc) and compared them with 80 patients who did not convert within two years (MCInc). Using 128-channel EEG recordings during eyes-closed resting state, the researchers investigated the evolution of functional connectivity (FC) in both groups.
What does the investigation show?
Findings reveal differences in the progression of functional connectivity between MCI patients who converted to AD and those who remained stable. These results support the use of advanced EEG-based connectivity analysis as a promising tool for distinguishing between high-risk and lower-risk MCI populations.
By identifying biomarkers that differentiate disease trajectories, AI-Mind contributes to the EU’s broader mission of developing innovative tools for early risk detection of dementia. The work presented at SEPNECA reflects the project’s commitment to bridging neuroscience research with clinical application, supporting earlier interventions and better patient outcomes.